Arti Dhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arti Dhar has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Audesh Bhat
Department of Life Science, Central University of Karnataka
19 shared publications Jaspreet Kalra
Department of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad, India
12 shared publicationsSureshbabu Mangali
Department of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana 500078, India
10 shared publications- Indu Dhar
Department of Clinical Science, University of Bergen , Pb 7804, Bergen 5020
9 shared publications Deepika Dasari
Department of Pharmacy, Birla Institute of Technology and Sciences (BITS) Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad, Telangana, 500078, India
8 shared publicationsAudesh Bhat
Department of Life Science, Central University of Karnataka, Kalaburagi, 585367, India
7 shared publications
Latest Publications
- 17 August 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2544-2559
Nesfatin-1 Deficiency Exacerbates Calcium Oxalate Monohydrate–Induced Cellular Injury in Renal Epithelial Cells
Calcium oxalate monohydrate (COM) crystals are major contributors to nephrolithiasis-associated renal tubular injury, primarily through mechanisms involving oxidative stress, inflammation, apoptosis, and epithelial–mesenchymal transition (EMT). While nesfatin-1 is known for its antioxidant and cytoprotective actions, the specific role of endogenous nesfatin-1 in regulating COM-induced epithelial injury has not been fully defined. In this study, nesfatin-1 was silenced using antisense oligonucleotides in NRK-52E and primary renal tubular epithelial cells to examine how loss of endogenous nesfatin-1 peptide influences cellular susceptibility to COM. COM exposure reduced nesfatin-1 levels, and this decline was markedly greater in the nesfatin-1 silenced + COM group. Silencing nesfatin-1 intensified COM-driven oxidative stress, as reflected by reduced catalase activity and increased levels of malondialdehyde, nitric oxide, and ROS. Pro-inflammatory markers including NF-κB, TNF-α, IL-6, and IL-1β were upregulated, whereas IL-10 was decreased. Apoptotic indicators such as elevated intracellular Ca2+, diminished Bcl-2, increased caspase-3 activation, and higher proportions of apoptotic and necrotic cells were also evident. EMT and fibrotic markers (TGF-β1, α-SMA, Smad2/3, Smad4, vimentin) were increased, alongside reduced E-cadherin expression. Exogenous nesfatin-1 mitigated oxidative, inflammatory, apoptotic, and fibrotic responses in COM-treated cells; however, these protective effects were minimal in nesfatin-1 silenced + COM cells. Overall, the findings demonstrate that endogenous nesfatin-1 is indispensable for maintaining epithelial stability under COM-induced stress, and its absence amplifies cellular injury while diminishes responsiveness to exogenous peptide. Nesfatin-1 thus emerges as a potential therapeutic target for limiting crystal-induced renal cells damage.
- 17 August 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2544-2559
Nesfatin-1 Deficiency Exacerbates Calcium Oxalate Monohydrate–Induced Cellular Injury in Renal Epithelial Cells
Calcium oxalate monohydrate (COM) crystals are major contributors to nephrolithiasis-associated renal tubular injury, primarily through mechanisms involving oxidative stress, inflammation, apoptosis, and epithelial–mesenchymal transition (EMT). While nesfatin-1 is known for its antioxidant and cytoprotective actions, the specific role of endogenous nesfatin-1 in regulating COM-induced epithelial injury has not been fully defined. In this study, nesfatin-1 was silenced using antisense oligonucleotides in NRK-52E and primary renal tubular epithelial cells to examine how loss of endogenous nesfatin-1 peptide influences cellular susceptibility to COM. COM exposure reduced nesfatin-1 levels, and this decline was markedly greater in the nesfatin-1 silenced + COM group. Silencing nesfatin-1 intensified COM-driven oxidative stress, as reflected by reduced catalase activity and increased levels of malondialdehyde, nitric oxide, and ROS. Pro-inflammatory markers including NF-κB, TNF-α, IL-6, and IL-1β were upregulated, whereas IL-10 was decreased. Apoptotic indicators such as elevated intracellular Ca2+, diminished Bcl-2, increased caspase-3 activation, and higher proportions of apoptotic and necrotic cells were also evident. EMT and fibrotic markers (TGF-β1, α-SMA, Smad2/3, Smad4, vimentin) were increased, alongside reduced E-cadherin expression. Exogenous nesfatin-1 mitigated oxidative, inflammatory, apoptotic, and fibrotic responses in COM-treated cells; however, these protective effects were minimal in nesfatin-1 silenced + COM cells. Overall, the findings demonstrate that endogenous nesfatin-1 is indispensable for maintaining epithelial stability under COM-induced stress, and its absence amplifies cellular injury while diminishes responsiveness to exogenous peptide. Nesfatin-1 thus emerges as a potential therapeutic target for limiting crystal-induced renal cells damage.
- 23 June 2026
- Published by Elsevier in Life Sciences
- Vol. 402, 124544
Nesfatin-1 mitigates calcium oxalate nephropathy in mice through GPR12 receptor modulation and PKCα/NADPH oxidase pathway inhibition
- 23 June 2026
- Published by Elsevier in Life Sciences
- Vol. 402, 124544
Nesfatin-1 mitigates calcium oxalate nephropathy in mice through GPR12 receptor modulation and PKCα/NADPH oxidase pathway inhibition
- 15 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117894
Nesfatin-1 attenuates renal interstitial fibrosis, oxidative stress, and inflammation through dual suppression of TGF-β1/Smad and NF-κB/GPR12 signaling
- 15 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117894
Nesfatin-1 attenuates renal interstitial fibrosis, oxidative stress, and inflammation through dual suppression of TGF-β1/Smad and NF-κB/GPR12 signaling
- 21 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1009, 178356
From cells to systems: A comprehensive perspective on In-Vitro, In-Vivo, and 3D culture models of heart failure
- 21 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1009, 178356
From cells to systems: A comprehensive perspective on In-Vitro, In-Vivo, and 3D culture models of heart failure
- 20 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1009, 178390
Angiotensin II-induced fibrosis is mediated by activation of FGFR1 pathway in renal epithelial cells: Attenuation by chimeric peptide
- 20 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1009, 178390
Angiotensin II-induced fibrosis is mediated by activation of FGFR1 pathway in renal epithelial cells: Attenuation by chimeric peptide
- 4 November 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (11) , e70579
Therapeutic Peptides Mitigates TLR4 Pathway Activation by Ang II in Renal and Vascular Smooth Muscle Cells
Angiotensin II (Ang II) plays a critical role in hypertension by activating toll‐like receptors (TLRs), particularly TLR4, which contributes to end‐organ damage and vascular injury. Ang 1‐7, a by‐product of the RAAS system, is known to counteract the deleterious effects of Ang II; however, the potential protective effects of the peptides, Ang 1‐7 and BNP in Ang II induced TLR4 activation remain unexplored. Therefore, our study primarily focused on investigating the effects of Ang 1‐7 and BNP on Ang II‐induced TLR4 activation in renal and primary vascular smooth muscle cells (VSMCs). We utilized renal epithelial cells (RECs), renal fibroblasts (RFbs), and VSMCs to assess end‐organ damage and vascular dysfunction mediated by Ang II. Gene expression of TLR4 and its downstream markers was evaluated via qPCR. Additionally, the impact of Ang 1‐7 and BNP on inflammatory, hypertrophic and fibrotic markers was assessed using qPCR and immunocytochemistry. Ang II stimulation led to the upregulation of TLR4‐mediated pathways in RECs and VSMCs, with a significant increase in hypertrophy, fibrosis, and inflammation observed in RECs and RFbs. Treatment with Ang 1‐7 and BNP notably reduced TLR4‐mediated injury markers and prevented the phenotypic switch. Furthermore, these peptides significantly inhibited Ang II‐induced TLR4 pathways in primary VSMCs and RECs. Importantly, the Ang II‐induced injury and phenotypic switch were driven by pro‐inflammatory and fibrotic markers, which were reversed by peptide treatment. These findings suggest that Ang 1‐7 and BNP offer a promising avenue for future research, peptide‐based strategies for protecting vital organs.
- 4 November 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (11) , e70579
Therapeutic Peptides Mitigates TLR4 Pathway Activation by Ang II in Renal and Vascular Smooth Muscle Cells
Angiotensin II (Ang II) plays a critical role in hypertension by activating toll‐like receptors (TLRs), particularly TLR4, which contributes to end‐organ damage and vascular injury. Ang 1‐7, a by‐product of the RAAS system, is known to counteract the deleterious effects of Ang II; however, the potential protective effects of the peptides, Ang 1‐7 and BNP in Ang II induced TLR4 activation remain unexplored. Therefore, our study primarily focused on investigating the effects of Ang 1‐7 and BNP on Ang II‐induced TLR4 activation in renal and primary vascular smooth muscle cells (VSMCs). We utilized renal epithelial cells (RECs), renal fibroblasts (RFbs), and VSMCs to assess end‐organ damage and vascular dysfunction mediated by Ang II. Gene expression of TLR4 and its downstream markers was evaluated via qPCR. Additionally, the impact of Ang 1‐7 and BNP on inflammatory, hypertrophic and fibrotic markers was assessed using qPCR and immunocytochemistry. Ang II stimulation led to the upregulation of TLR4‐mediated pathways in RECs and VSMCs, with a significant increase in hypertrophy, fibrosis, and inflammation observed in RECs and RFbs. Treatment with Ang 1‐7 and BNP notably reduced TLR4‐mediated injury markers and prevented the phenotypic switch. Furthermore, these peptides significantly inhibited Ang II‐induced TLR4 pathways in primary VSMCs and RECs. Importantly, the Ang II‐induced injury and phenotypic switch were driven by pro‐inflammatory and fibrotic markers, which were reversed by peptide treatment. These findings suggest that Ang 1‐7 and BNP offer a promising avenue for future research, peptide‐based strategies for protecting vital organs.
- 12 June 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 450 (2) , 114652
PKR inhibition reduces high glucose and H2O2-induced injury in rat renal epithelial cells by suppressing the sonic hedgehog pathway
- 12 June 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 450 (2) , 114652
PKR inhibition reduces high glucose and H2O2-induced injury in rat renal epithelial cells by suppressing the sonic hedgehog pathway
- 18 May 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (6) , e70302
Model Systems of Chronic Kidney Disease: A Detailed Overview and Recent Advances
Experimental model systems, especially animal models, are indispensable tools to study human diseases and to develop new therapeutics. Chronic kidney disease (CKD) is a major global health problem having significantly higher rate of morbidity and mortality. In a pursuit to enhance our understanding of the pathophysiology of CKD and to develop effective treatments, three main model systems, namely In Vivo, In Vitro, and computational, are commonly employed. Each of these models has its own advantages and disadvantages, and despite some limitations, each model has provided valuable insights into CKD progression and the effect of therapeutic interventions. The emergence of organotypic models, such as iPSC‐derived kidney organoids and tubuloids, offers physiologically relevant In Vitro systems that more accurately mimic the human kidney development and disease. With the advent of artificial intelligence (AI), a new and potent fourth model is in the making that is expected to revolutionize the management of complex human diseases. Our discussion in this review will mainly revolve around the three major model systems of CKD; In Vivo, In Vitro organotypic, and the computational model with a brief discussion on the AI model. By comprehensively evaluating these model systems, this review aims to provide a foundation for future CKD research and clinical practice.
- 18 May 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (6) , e70302
Model Systems of Chronic Kidney Disease: A Detailed Overview and Recent Advances
Experimental model systems, especially animal models, are indispensable tools to study human diseases and to develop new therapeutics. Chronic kidney disease (CKD) is a major global health problem having significantly higher rate of morbidity and mortality. In a pursuit to enhance our understanding of the pathophysiology of CKD and to develop effective treatments, three main model systems, namely In Vivo, In Vitro, and computational, are commonly employed. Each of these models has its own advantages and disadvantages, and despite some limitations, each model has provided valuable insights into CKD progression and the effect of therapeutic interventions. The emergence of organotypic models, such as iPSC‐derived kidney organoids and tubuloids, offers physiologically relevant In Vitro systems that more accurately mimic the human kidney development and disease. With the advent of artificial intelligence (AI), a new and potent fourth model is in the making that is expected to revolutionize the management of complex human diseases. Our discussion in this review will mainly revolve around the three major model systems of CKD; In Vivo, In Vitro organotypic, and the computational model with a brief discussion on the AI model. By comprehensively evaluating these model systems, this review aims to provide a foundation for future CKD research and clinical practice.
- 13 May 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 225, 116284
Renoprotective effect of Nesfatin-1 in Adenine-Induced Chronic kidney Disease: An in vitro and in vivo study
- 13 May 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 225, 116284
Renoprotective effect of Nesfatin-1 in Adenine-Induced Chronic kidney Disease: An in vitro and in vivo study
- 8 March 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (4) , 167110
Co-activation of Mas and pGCA receptors suppresses Endothelin-1-induced endothelial dysfunction via nitric oxide/cGMP system
- 8 March 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (4) , 167110
Co-activation of Mas and pGCA receptors suppresses Endothelin-1-induced endothelial dysfunction via nitric oxide/cGMP system